GlycoNex Inc (4168)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:GlycoNex Inc (4168) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014275
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GlycoNex Inc (GlycoNex) is a drug discovery company that conducts research and development in glycosphingolipid antigen and human monoclonal antibody technologies to develop cancer drugs. The company carries out antibody drug development through various technology platforms such as glycosphingolipid antigen production and identification, cancer drug screening, monoclonal antibody production, stable cell line production for monoclonal antibody and pharmacokinetics assessment. It provides glycobind antibody reagents. GlycoNex offers services such as functional evaluation, antibody engineering and antibody characterization. The company has an antibody bank that acts as a resource for future drug development. GlycoNex is headquartered in New Taipei City, Taiwan.

GlycoNex Inc (4168) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
GlycoNex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
GlycoNex Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
GlycoNex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
GlycoNex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
GlycoNex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
GlycoNex Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
GlycoNex Enters Into Agreement With Mitsubishi Gas Chemical For Cancer Antibody 10
Equity Offering 11
GlycoNex Announces Private Placement of Shares 11
GlycoNex Completes Public Offering Of Shares For US$3 Million 12
GlycoNex Raises USD24 Million in Rights Offering of Shares 13
GlycoNex Announces Private Placement Of Shares For US$9.2 Million 14
GlycoNex Completes IPO 15
Debt Offering 16
GlycoNex Announces Public Offering Of Bonds Due 2016 For US$10 Million 16
GlycoNex Inc – Key Competitors 17
GlycoNex Inc – Key Employees 18
GlycoNex Inc – Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
GlycoNex Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
GlycoNex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
GlycoNex Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
GlycoNex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
GlycoNex Inc, Deals By Therapy Area, 2011 to YTD 2017 8
GlycoNex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
GlycoNex Enters Into Agreement With Mitsubishi Gas Chemical For Cancer Antibody 10
GlycoNex Announces Private Placement of Shares 11
GlycoNex Completes Public Offering Of Shares For US$3 Million 12
GlycoNex Raises USD24 Million in Rights Offering of Shares 13
GlycoNex Announces Private Placement Of Shares For US$9.2 Million 14
GlycoNex Completes IPO 15
GlycoNex Announces Public Offering Of Bonds Due 2016 For US$10 Million 16
GlycoNex Inc, Key Competitors 17
GlycoNex Inc, Key Employees 18

★海外企業調査レポート[GlycoNex Inc (4168)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Viridian Group Investments Ltd:企業の戦略的SWOT分析
    Viridian Group Investments Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Protagonist Therapeutics Inc (PTGX):企業の財務・戦略的SWOT分析
    Protagonist Therapeutics Inc (PTGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Phillips 66 (PSX):企業の財務・戦略的SWOT分析
    Phillips 66 (PSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Senetas Corporation Limited:企業の戦略・SWOT・財務分析
    Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Air Products and Chemicals Inc (APD):企業の財務・戦略的SWOT分析
    Air Products and Chemicals Inc (APD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • PipeHawk Plc:企業の戦略・SWOT・財務分析
    PipeHawk Plc - Strategy, SWOT and Corporate Finance Report Summary PipeHawk Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Standard Chartered Bank Kenya Ltd:企業の戦略・SWOT・財務分析
    Standard Chartered Bank Kenya Ltd - Strategy, SWOT and Corporate Finance Report Summary Standard Chartered Bank Kenya Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • SDN Company Ltd (099220):電力:M&Aディール及び事業提携情報
    Summary SDN Company Ltd (SDN Company), formerly Seoul Marine Co Ltd is a diversified company that operates through its business divisions such as photovoltaic, engine, and shipbuilding divisions. The company’s photovoltaic business division manufactures solar inverters, solar panels, solar trackers, …
  • TransAtlantic Petroleum Ltd (TAT):石油・ガス:M&Aディール及び事業提携情報
    Summary TransAtlantic Petroleum Ltd. (TransAtlantic) is an upstream energy company that acquires, develops, explores for, and produces crude oil and natural gas. It holds interests in developed and undeveloped oil and natural gas properties in Turkey and Bulgaria. The company operates onshore explor …
  • SThree Plc (STHR):企業の財務・戦略的SWOT分析
    Summary SThree Plc (Sthree) is a staffing company that offers permanent and contract staffing business. The company operates through its sectors such as information and communications technology (ICT), energy, engineering, life sciences, banking and finance. Its business brands such as Computer Futu …
  • Archrock Partners LP:企業のM&A・事業提携・投資動向
    Archrock Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Archrock Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Eureka Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Eureka Therapeutics Inc (Eureka Therapeutics) is a clinical stage biotechnology company which focuses on the development of novel T cell immunotherapies for the treatment of solid tumors. Its pipeline encompasses drug candidates for various indications such as liver cancer, hematological can …
  • The Independent Order of Foresters:企業の戦略的SWOT分析
    The Independent Order of Foresters - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Havfisk ASA:企業の戦略・SWOT・財務分析
    Havfisk ASA - Strategy, SWOT and Corporate Finance Report Summary Havfisk ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Companhia Energetica de Sao Paulo:発電所・企業SWOT分析
    Companhia Energetica de Sao Paulo - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Colonial Group Inc.:企業の戦略・SWOT・財務分析
    Colonial Group Inc. - Strategy, SWOT and Corporate Finance Report Summary Colonial Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Shri Lakshmi Cotsyn Ltd.:企業の戦略・SWOT・財務分析
    Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • VivaCell Biotechnology Espana SL:製薬・医療:M&Aディール及び事業提携情報
    Summary VivaCell Biotechnology Espana SL (VivaCell Biotechnology), a subsidiary of VivaCell Biotechnology GmbH, is a preclinical-stage pharmaceutical company that develops medicinal derivatives. The company's products comprise CDE-001, VCE-003.2 and VCE-004.8. It provides research and development, c …
  • Wellcome Trust:企業のM&A・事業提携・投資動向
    Wellcome Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wellcome Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Promedior Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Promedior Inc (Promedior) is a clinical-stage biotechnology company that develops medicines for the treatment of fibrotic disorders. The company’s pipeline products include PRM-151 and PRM-167. PRM-151 is used in the treatment of rare systemic fibrotic diseases such as myelofibrosis and idio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆